Earn Your Leisure

Welcome back to another insightful clip of Market Mondays! In this clip hosts, Troy Millings and Ian Dunlap, dive deep into the recent movements in Eli Lilly's stock. With a 26% drop from its peak of $972 to $718, many investors are questioning whether this is a cause for alarm or a golden opportunity to buy.Ian and Troy break down the situation, examining the factors behind the stock's recent performance. They consider the influence of political lobbying and the potential impact of RFK's policies on the pharmaceutical space. The insight provided includes a crucial lesson on understanding quarterly ranges and recognizing when stock prices revert to their normal range after periods of exuberance.Discussing the pharmaceutical giants Eli Lilly and Novo Nordisk, our hosts highlight the strengths of both companies but ultimately favor Eli Lilly for its better management, competitive advantages, and robust product portfolio. Despite recent earnings misses on key products like Zip Hound and Mounjaro, Ian